Communiqués Alzamend Neuro, Inc.

Actions

ALZN

US02262M6057

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
1,720 ^USD	+1,18 %		+1,18 %	-5,49 %

10/09	Alzamend Neuro, Inc. publie ses résultats pour le premier trimestre clos le 31 juillet 2026	CI
20/08	Alzamend Neuro annonce l'acceptation de ses résultats d'IRMf au repos pour AL001 pour une présentation par affiche lors de Neuroscience 2026	CI

Communiqués

20/08	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
18/08	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
22/07	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
07/04	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
26/03	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR
16/03	Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	PR
19/11	Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital	PR
28/07/25	Alzamend Neuro to Present at the 2025 Military Health System Research Symposium	AQ
23/07/25	Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs	AQ
16/06/25	Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule	AQ
29/05/25	Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital	AQ
19/05/25	Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital	AQ
13/05/25	Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital	AQ
08/05/25	Alzamend Neuro Announces Reverse Stock Split	AQ
07/05/25	Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital	AQ
25/03/25	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital	AQ
18/03/25	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital	AQ
11/03/25	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital	AQ
04/03/25	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital	AQ
25/02/25	Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital	AQ
25/02/25	Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital	GL
19/02/25	Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital	BU
15/01/25	Alzamend Neuro to Present at the Sequire Investor Summit	BU
18/12/24	Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo	BU
12/12/24	Alzamend Neuro : Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs Form 8 K	PU